BMO Capital Markets Upgrades ICON to Outperform with Price Target Raised to $130
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ICLR?
Source: seekingalpha
- Rating Upgrade: BMO Capital Markets upgraded ICON Public Limited (ICLR) from Market Perform to Outperform and raised its price target from $100 to $130, reflecting an attractive valuation after the stock has lost nearly 44% over the past 12 months.
- Financial Uncertainty: Despite concerns regarding uncertainty over its upcoming Q4 2025 financials, particularly related to an ongoing accounting probe, analyst Sean Dodge believes the valuation remains compelling in the current market environment.
- Valuation Analysis: Dodge noted that ICLR is trading at an 8.3x multiple, at a “multi-decade low,” making it an attractive entry point for investors, especially as its valuation “overly discounts” the associated risks and long-term AI fears affecting the CRO sector.
- Market Reaction: ICON's shares dropped in February after the company withdrew its 2025 financial guidance, with the audit committee's investigation still pending; however, the market's rebound indicates investor confidence in its future potential.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ICLR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ICLR
Wall Street analysts forecast ICLR stock price to rise
13 Analyst Rating
6 Buy
7 Hold
0 Sell
Moderate Buy
Current: 99.990
Low
172.00
Averages
202.67
High
222.00
Current: 99.990
Low
172.00
Averages
202.67
High
222.00
About ICLR
ICON Public Limited Company is a healthcare intelligence and clinical research organization. The Company is engaged in providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. It offers a range of specialized services to assist pharmaceutical, biotechnology and medical device companies to bring new drugs and devices to market faster. The Company's services include clinical research services, commercial positioning, consulting, early phase, strategic solutions, laboratories, language services, medical imaging, real world intelligence, site and patient solutions, COVID-19 clinical operation and decentralized and hybrid clinical solutions. It also provides its full range of clinical, consulting and commercial services across several sectors, which include biosimilars, biotechnology, government and public health solutions, medical devices and pharmaceuticals.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BMO Capital Markets Upgrades ICON to Outperform with Price Target Raised to $130
- Rating Upgrade: BMO Capital Markets upgraded ICON Public Limited (ICLR) from Market Perform to Outperform and raised its price target from $100 to $130, reflecting an attractive valuation after the stock has lost nearly 44% over the past 12 months.
- Financial Uncertainty: Despite concerns regarding uncertainty over its upcoming Q4 2025 financials, particularly related to an ongoing accounting probe, analyst Sean Dodge believes the valuation remains compelling in the current market environment.
- Valuation Analysis: Dodge noted that ICLR is trading at an 8.3x multiple, at a “multi-decade low,” making it an attractive entry point for investors, especially as its valuation “overly discounts” the associated risks and long-term AI fears affecting the CRO sector.
- Market Reaction: ICON's shares dropped in February after the company withdrew its 2025 financial guidance, with the audit committee's investigation still pending; however, the market's rebound indicates investor confidence in its future potential.
See More
Wall Street's Latest Ratings: Apple and Dell Rated Buy
- Apple and Dell Benefiting: Goldman Sachs reiterates Buy ratings for Apple (AAPL) and Dell (DELL), citing increased demand for PC hardware driven by the rise of open-source autonomous AI agents, which is expected to enhance their market performance.
- Abercrombie & Fitch Coverage Initiated: Needham initiates coverage on Abercrombie & Fitch (ANF) with a Buy rating and a $108 price target, believing that after a challenging FY25, the company's fundamentals are stabilizing, making it attractive for investors.
- Spotify Performance Outlook: Daiwa rates Spotify Technology (SPOT) as Outperform with a $535 price target, based on expectations of steady revenue growth, indicating confidence in its future development.
- Somnigroup International Upgrade: Jefferies upgrades Somnigroup International (SGI) from Hold to Buy, noting that SGI shares have fallen about 17% since the start of the Iran war, yet its valuation remains attractive, reflecting market confidence in its future growth potential.
See More
BMO Upgrades ICON PLC to Outperform, Increases Target Price from $100 to $130
Company Performance: Icon PLC has reported strong market performance, indicating positive growth and stability.
Target Price Increase: The company has raised its target price from $100 to $130, reflecting increased investor confidence and market expectations.
See More
ICON plc Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ICON plc has engaged in securities fraud or other unlawful business practices, indicating serious concerns regarding the company's governance and compliance.
- Earnings Release Delay: ICON announced it intends to release its fourth quarter and full year 2025 earnings results by April 30, 2026, reflecting pressure on the company regarding financial transparency, which could impact investor confidence.
- Internal Investigation Initiated: The Audit Committee has launched an internal investigation into accounting practices and controls since October 2025, highlighting potential issues in financial reporting that may lead to stricter regulatory scrutiny.
- Significant Stock Price Drop: Following the announcement on February 12, 2026, ICON's stock price plummeted by 39.85%, falling $53.06 to close at $80.08, demonstrating strong market concerns about the company's financial health.
See More
ICON plc Under Investigation for Possible Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ICON plc has engaged in securities fraud or other unlawful business practices, prompting investors to contact the firm for further information, indicating serious concerns regarding corporate governance.
- Delayed Earnings Release: ICON announced it intends to release its fourth quarter and full year 2025 earnings results by April 30, 2026, while initiating an internal investigation into accounting practices and controls, which may undermine investor confidence.
- Significant Stock Price Drop: Following the announcement on February 12, 2026, ICON's stock plummeted by 39.85%, falling $53.06 to close at $80.08, reflecting market apprehension about the company's financial transparency.
- Legal Action Risks: As the investigation unfolds, ICON faces potential class action lawsuits, with Pomerantz LLP, a prominent securities litigation firm, likely to provide legal support to affected investors, further intensifying the company's legal and financial pressures.
See More
ICON Public Limited Company Under Investigation for Securities Violations
- Audit Committee Investigation: On February 12, 2026, ICON disclosed that its Audit Committee is investigating certain accounting practices and internal controls, including revenue recognition methods for fiscal years 2023 to 2025, with expectations of reporting material weaknesses that could impact financial transparency.
- Financial Results Delayed: Due to the ongoing investigation, ICON has postponed the release of its fourth quarter and full year 2025 financial results and withdrawn its previously issued 2025 guidance, which is likely to negatively affect investor confidence.
- Significant Stock Price Drop: Following the announcement of the investigation, ICON's stock price plummeted by $53.06, or approximately 40%, from $133.14 per share on February 11, 2026, closing at $80.08, reflecting market concerns about the company's future financial health.
- Increased Legal Risks: Although no lawsuits have been filed yet, the ongoing investigation raises the risk of potential claims under federal securities laws, prompting investors to closely monitor developments to protect their interests.
See More
BMO Capital Markets Upgrades ICON to Outperform with Price Target Raised to $130
- Rating Upgrade: BMO Capital Markets upgraded ICON Public Limited (ICLR) from Market Perform to Outperform and raised its price target from $100 to $130, reflecting an attractive valuation after the stock has lost nearly 44% over the past 12 months.
- Financial Uncertainty: Despite concerns regarding uncertainty over its upcoming Q4 2025 financials, particularly related to an ongoing accounting probe, analyst Sean Dodge believes the valuation remains compelling in the current market environment.
- Valuation Analysis: Dodge noted that ICLR is trading at an 8.3x multiple, at a “multi-decade low,” making it an attractive entry point for investors, especially as its valuation “overly discounts” the associated risks and long-term AI fears affecting the CRO sector.
- Market Reaction: ICON's shares dropped in February after the company withdrew its 2025 financial guidance, with the audit committee's investigation still pending; however, the market's rebound indicates investor confidence in its future potential.
See More
Wall Street's Latest Ratings: Apple and Dell Rated Buy
- Apple and Dell Benefiting: Goldman Sachs reiterates Buy ratings for Apple (AAPL) and Dell (DELL), citing increased demand for PC hardware driven by the rise of open-source autonomous AI agents, which is expected to enhance their market performance.
- Abercrombie & Fitch Coverage Initiated: Needham initiates coverage on Abercrombie & Fitch (ANF) with a Buy rating and a $108 price target, believing that after a challenging FY25, the company's fundamentals are stabilizing, making it attractive for investors.
- Spotify Performance Outlook: Daiwa rates Spotify Technology (SPOT) as Outperform with a $535 price target, based on expectations of steady revenue growth, indicating confidence in its future development.
- Somnigroup International Upgrade: Jefferies upgrades Somnigroup International (SGI) from Hold to Buy, noting that SGI shares have fallen about 17% since the start of the Iran war, yet its valuation remains attractive, reflecting market confidence in its future growth potential.
See More
BMO Upgrades ICON PLC to Outperform, Increases Target Price from $100 to $130
Company Performance: Icon PLC has reported strong market performance, indicating positive growth and stability.
Target Price Increase: The company has raised its target price from $100 to $130, reflecting increased investor confidence and market expectations.
See More
ICON plc Under Investigation for Securities Fraud Claims
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ICON plc has engaged in securities fraud or other unlawful business practices, indicating serious concerns regarding the company's governance and compliance.
- Earnings Release Delay: ICON announced it intends to release its fourth quarter and full year 2025 earnings results by April 30, 2026, reflecting pressure on the company regarding financial transparency, which could impact investor confidence.
- Internal Investigation Initiated: The Audit Committee has launched an internal investigation into accounting practices and controls since October 2025, highlighting potential issues in financial reporting that may lead to stricter regulatory scrutiny.
- Significant Stock Price Drop: Following the announcement on February 12, 2026, ICON's stock price plummeted by 39.85%, falling $53.06 to close at $80.08, demonstrating strong market concerns about the company's financial health.
See More
ICON plc Under Investigation for Possible Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether ICON plc has engaged in securities fraud or other unlawful business practices, prompting investors to contact the firm for further information, indicating serious concerns regarding corporate governance.
- Delayed Earnings Release: ICON announced it intends to release its fourth quarter and full year 2025 earnings results by April 30, 2026, while initiating an internal investigation into accounting practices and controls, which may undermine investor confidence.
- Significant Stock Price Drop: Following the announcement on February 12, 2026, ICON's stock plummeted by 39.85%, falling $53.06 to close at $80.08, reflecting market apprehension about the company's financial transparency.
- Legal Action Risks: As the investigation unfolds, ICON faces potential class action lawsuits, with Pomerantz LLP, a prominent securities litigation firm, likely to provide legal support to affected investors, further intensifying the company's legal and financial pressures.
See More
ICON Public Limited Company Under Investigation for Securities Violations
- Audit Committee Investigation: On February 12, 2026, ICON disclosed that its Audit Committee is investigating certain accounting practices and internal controls, including revenue recognition methods for fiscal years 2023 to 2025, with expectations of reporting material weaknesses that could impact financial transparency.
- Financial Results Delayed: Due to the ongoing investigation, ICON has postponed the release of its fourth quarter and full year 2025 financial results and withdrawn its previously issued 2025 guidance, which is likely to negatively affect investor confidence.
- Significant Stock Price Drop: Following the announcement of the investigation, ICON's stock price plummeted by $53.06, or approximately 40%, from $133.14 per share on February 11, 2026, closing at $80.08, reflecting market concerns about the company's future financial health.
- Increased Legal Risks: Although no lawsuits have been filed yet, the ongoing investigation raises the risk of potential claims under federal securities laws, prompting investors to closely monitor developments to protect their interests.
See More
